Nantahala Capital Management LLC Purchases 197,756 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Nantahala Capital Management LLC grew its position in Kodiak Sciences Inc. (NASDAQ:KOD) by 287.2% during the 4th quarter, HoldingsChannel reports. The firm owned 266,613 shares of the company’s stock after purchasing an additional 197,756 shares during the quarter. Nantahala Capital Management LLC’s holdings in Kodiak Sciences were worth $2,653,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its position in Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock valued at $32,000 after acquiring an additional 2,988 shares in the last quarter. American Century Companies Inc. lifted its position in Kodiak Sciences by 6.2% during the 4th quarter. American Century Companies Inc. now owns 59,967 shares of the company’s stock worth $597,000 after buying an additional 3,515 shares in the last quarter. US Bancorp DE bought a new stake in Kodiak Sciences during the 4th quarter worth about $40,000. Bank of New York Mellon Corp lifted its position in Kodiak Sciences by 5.3% during the 4th quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company’s stock worth $976,000 after buying an additional 4,927 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Kodiak Sciences by 2.9% during the 4th quarter. Northern Trust Corp now owns 269,597 shares of the company’s stock worth $2,682,000 after buying an additional 7,678 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.

Kodiak Sciences Stock Performance

Shares of KOD opened at $4.11 on Monday. Kodiak Sciences Inc. has a 52 week low of $1.92 and a 52 week high of $11.60. The firm has a market cap of $216.79 million, a P/E ratio of -1.13 and a beta of 2.40. The firm’s 50-day simple moving average is $3.27 and its 200 day simple moving average is $5.44.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. As a group, equities analysts forecast that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.